Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Short term Debt: 2020-2025

Historic Short term Debt for Puma Biotechnology (PBYI) over the last 4 years, with Sep 2025 value amounting to $33.7 million.

  • Puma Biotechnology's Short term Debt fell 25.62% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year decrease of 25.62%. This contributed to the annual value of $45.3 million for FY2024, which is 33.33% up from last year.
  • Puma Biotechnology's Short term Debt amounted to $33.7 million in Q3 2025, which was down 0.83% from $34.0 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Short term Debt registered a high of $45.3 million during Q1 2024, and its lowest value of $11.3 million during Q2 2023.
  • In the last 3 years, Puma Biotechnology's Short term Debt had a median value of $39.7 million in 2023 and averaged $36.2 million.
  • In the last 5 years, Puma Biotechnology's Short term Debt spiked by 300.01% in 2024 and then fell by 25.62% in 2025.
  • Puma Biotechnology's Short term Debt (Quarterly) stood at $31.4 million in 2021, then reached $34.0 million in 2023, then surged by 33.33% to $45.3 million in 2024, then decreased by 25.62% to $33.7 million in 2025.
  • Its Short term Debt stands at $33.7 million for Q3 2025, versus $34.0 million for Q2 2025 and $45.3 million for Q1 2025.